SVN-002

About SVN-002

SVN-002 is a novel combination therapy consisting of a patent-pending proprietary esketamine oral thin film with manualised psycho-social support to treat moderate to severe alcohol use disorder in the US.

Clinical evidence

Phase 1 was successfully completed by LTS Lohmann and in-licensed by Solvonis.

Clinical development & regulatory pathway

Now in Phase 2b planning, with a positive Pre-Investigational New Drug Application meeting with the US Food and Drug Administration (FDA) in December 2024, with support for a 505(b)(2) pathway.

Intellectual property

  • Formulation patents internationally by LTS Lohmann Systems AG.

  • Method of Use patents filed internationally by Solvonis.